Related Experiment Videos

[Laboratory and clinical studies on T-1982 (cefbuperazone) in the field of pediatrics]

Insights

T-1982 (cefbuperazone) shows strong antibacterial activity against E. coli and K. pneumoniae, with good clinical efficacy in pediatric infections. This new antibiotic demonstrates promising results in treating various infections.

Area of Science:

  • Microbiology
  • Pharmacology
  • Clinical Medicine

Background:

  • T-1982 (cefbuperazone) is a novel 7 alpha-methoxycephem antibiotic.
  • Evaluation of its antibacterial spectrum and clinical utility is essential.

Purpose of the Study:

  • To assess the in vitro antibacterial activity of T-1982 against key clinical isolates.
  • To determine the pharmacokinetic profile and clinical efficacy of T-1982 in pediatric patients.

Main Methods:

  • In vitro susceptibility testing of T-1982 against S. aureus, E. coli, K. pneumoniae, S. marcescens, P. mirabilis, and P. aeruginosa.
  • Pharmacokinetic studies involving intravenous administration in pediatric patients to measure serum and urinary levels.
  • Clinical trial evaluating T-1982 efficacy and safety in pediatric patients with various infections.

Main Results:

  • T-1982 demonstrated potent activity against E. coli, K. pneumoniae, and P. mirabilis (MICs ≤ 0.39 µg/ml).
  • It showed moderate activity against S. aureus and S. marcescens, but limited activity against P. aeruginosa.
  • Pharmacokinetic studies revealed favorable serum levels and urinary recovery rates. Clinical trials showed a 94.4% efficacy rate in pediatric patients with infections, with minimal adverse effects.

Conclusions:

  • T-1982 exhibits a favorable antibacterial spectrum, particularly against Gram-negative bacteria.
  • The antibiotic possesses suitable pharmacokinetic properties for clinical use in pediatric populations.
  • T-1982 is an effective and safe therapeutic option for treating pediatric infections.

Related Concept Videos